Capricor Therapeutics Sets Sights on Historic Approval for Groundbreaking Duchenne Muscular Dystrophy Treatment
In a major milestone for Capricor Therapeutics, the company has announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for Deramiocel, a treatment designed to address both skeletal and cardiac disease manifestations of Duchenne muscular dystrophy.
The FDA has assigned a PDUFA target action date of August 22, 2026, marking a significant regulatory milestone for Capricor and the patient community. The BLA seeks full approval of Deramiocel, which has the potential to become the first therapy designed to address both skeletal and cardiac disease manifestations of Duchenne muscular dystrophy.
According to Linda, CEO of Capricor Therapeutics, the company's highest priority is execution, working closely with the FDA, preparing for a potential commercial launch, and continuing to build the capabilities required of a world-class commercial-stage biotechnology company. "We believe that distinction is highly meaningful, particularly given that cardiomyopathy remains one of the most serious and life-limiting aspects of this disease," she said.
The HOPE-3 trial, which was released in late 2025, serves as the foundation for potential approval and commercial launch. The trial enrolled 106 patients and met its primary efficacy endpoint of the Performance of the Upper Limb (PUL), as well as all Type I error-controlled secondary endpoints.
Capricor Therapeutics has a strong balance sheet position, which it believes will enable the company to execute on its next phase of growth. The company's current corporate mission is to build an infrastructure to support launch and commercialization of Deramiocel, as well as to expand its pipeline to treat other indications.
The acceptance of the BLA by the FDA represents a major step forward for Capricor Therapeutics and the patient community. If approved, Deramiocel will be a groundbreaking treatment that has the potential to make a significant difference in the lives of patients with Duchenne muscular dystrophy.
